Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
3.
N Engl J Med ; 355(22): 2283-96, 2006 Nov 30.
Article in English | MEDLINE | ID: mdl-17135583

ABSTRACT

BACKGROUND: Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV). METHODS: We randomly assigned persons infected with HIV who had a CD4+ cell count of more than 350 per cubic millimeter to the continuous use of antiretroviral therapy (the viral suppression group) or the episodic use of antiretroviral therapy (the drug conservation group). Episodic use involved the deferral of therapy until the CD4+ count decreased to less than 250 per cubic millimeter and then the use of therapy until the CD4+ count increased to more than 350 per cubic millimeter. The primary end point was the development of an opportunistic disease or death from any cause. An important secondary end point was major cardiovascular, renal, or hepatic disease. RESULTS: A total of 5472 participants (2720 assigned to drug conservation and 2752 to viral suppression) were followed for an average of 16 months before the protocol was modified for the drug conservation group. At baseline, the median and nadir CD4+ counts were 597 per cubic millimeter and 250 per cubic millimeter, respectively, and 71.7% of participants had plasma HIV RNA levels of 400 copies or less per milliliter. Opportunistic disease or death from any cause occurred in 120 participants (3.3 events per 100 person-years) in the drug conservation group and 47 participants (1.3 per 100 person-years) in the viral suppression group (hazard ratio for the drug conservation group vs. the viral suppression group, 2.6; 95% confidence interval [CI], 1.9 to 3.7; P<0.001). Hazard ratios for death from any cause and for major cardiovascular, renal, and hepatic disease were 1.8 (95% CI, 1.2 to 2.9; P=0.007) and 1.7 (95% CI, 1.1 to 2.5; P=0.009), respectively. Adjustment for the latest CD4+ count and HIV RNA level (as time-updated covariates) reduced the hazard ratio for the primary end point from 2.6 to 1.5 (95% CI, 1.0 to 2.1). CONCLUSIONS: Episodic antiretroviral therapy guided by the CD4+ count, as used in our study, significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antiretroviral therapy, largely as a consequence of lowering the CD4+ cell count and increasing the viral load. Episodic antiretroviral therapy does not reduce the risk of adverse events that have been associated with antiretroviral therapy. (ClinicalTrials.gov number, NCT00027352 [ClinicalTrials.gov].).


Subject(s)
Anti-Retroviral Agents/administration & dosage , CD4 Lymphocyte Count , HIV Infections/drug therapy , AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/mortality , Adult , Cardiovascular Diseases/epidemiology , Drug Administration Schedule , Female , Follow-Up Studies , HIV/genetics , HIV/isolation & purification , HIV Infections/immunology , HIV Infections/mortality , Humans , Kidney Diseases/epidemiology , Liver Diseases/epidemiology , Male , Middle Aged , Proportional Hazards Models , RNA, Viral/blood
4.
J Viral Hepat ; 12(4): 414-20, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15985013

ABSTRACT

The effect of interleukin-2 (IL-2) on the plasma levels of hepatitis C RNA (HCV-RNA) has varied in published reports. We measured the impact of IL-2 on plasma HCV RNA levels in 54 human immunodeficiency virus (HIV)/HCV coinfected patients enrolled in a randomized trial of 512 participants designed to compare the virologic and immunologic effects of cycled IL-2 plus antiretroviral therapy (ART) vs ART alone in the treatment of HIV in patients with CD4 cell counts > or =300 cells/mm(3). The mean decreases in average HCV RNA levels (copies/mL, log (10)) were 0.28 log in the IL-2 group (n = 26) and 0.04 log in the ART alone group (n = 28) at 12 months (P = 0.18). The changes in HCV RNA level were not associated with baseline or nadir CD4 cell counts, baseline aspartate aminotransferanse, CD4 cell response to IL-2, or changes in plasma HIV RNA values. Compared with those participants who only had HIV, the HIV/HCV co-infected patients did not have a significantly different CD4 cell response to IL-2 therapy. Intermittent IL-2 therapy does not produce a significant sustained decrease in plasma HCV RNA levels among patients co-infected with HIV/HCV who are on highly active ART.


Subject(s)
Antiviral Agents/therapeutic use , HIV Infections/complications , Hepacivirus/drug effects , Hepatitis C/drug therapy , Interleukin-2/therapeutic use , RNA, Viral/blood , Adult , Antiretroviral Therapy, Highly Active , Antiviral Agents/administration & dosage , Aspartate Aminotransferases/blood , CD4 Lymphocyte Count , Female , HIV/drug effects , HIV Infections/drug therapy , Hepatitis C/complications , Hepatitis C/virology , Humans , Interleukin-2/administration & dosage , Male
5.
HIV Med ; 6(2): 79-90, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15807713

ABSTRACT

BACKGROUND: Metabolic abnormalities are common in HIV-infected individuals and, although multifactorial in origin, have been strongly associated with antiretroviral therapy. METHODS: Using automated claims and clinical databases, combined with medical record data, we evaluated the burden of dyslipidaemia (DYS) and associated metabolic abnormalities among a cohort of 900 HIV-infected patients aged 18 years and older who received their care from a large multispecialty medical group between 1 January 1996 and 30 June 2002. A Cox proportional hazards model for DYS was developed. Resource use was compiled and subsequently costed with stratification to account for variable length of follow-up. RESULTS: Mean follow-up time was 3.3 years. DYS was present in 54% of the cohort and 3.4% experienced a cardiovascular (CV) event. Both unadjusted and adjusted results found patients with dyslipidaemia and cardiovascular events significantly more likely to have received protease inhibitor (PI) treatment for longer periods of time. In the Cox proportional hazards model the following factors were significantly associated with an increased risk for DYS: older age, white race, PI use and male sex. Diagnoses of hypertension, hepatitis C virus infection, depression or opportunistic infections were all negatively associated with a DYS diagnosis. When controlled for length of follow up, patients with DYS (and no CV-related events) incurred greater median and mean total average costs than patients without DYS or CV-related events. For patients with more than 2 years of follow up, these total cost differences were statistically significant (P<0.05). CONCLUSIONS: These findings indicate that DYS is common among patients with HIV infection and is associated with increased use of medical resources.


Subject(s)
Antiviral Agents/therapeutic use , Cardiovascular Diseases/virology , HIV Infections/complications , HIV Protease Inhibitors/therapeutic use , Hyperlipidemias/etiology , Hypolipidemic Agents/therapeutic use , Adult , Age Factors , Antiretroviral Therapy, Highly Active , Antiviral Agents/economics , Cardiovascular Diseases/economics , Databases, Factual , Drug Costs , Female , Follow-Up Studies , HIV Infections/drug therapy , HIV Infections/economics , HIV Protease Inhibitors/economics , Health Care Costs , Humans , Hyperlipidemias/economics , Hypolipidemic Agents/economics , Male , Proportional Hazards Models , Retrospective Studies , Sex Factors , White People
7.
J Psychosom Res ; 51(4): 577-87, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11595246

ABSTRACT

OBJECTIVE: This study examined associations of two types of optimism (Peterson and Seligman's optimistic explanatory style and Scheier and Carver's dispositional optimism) with each other as well as with symptoms and immune status among human immunodeficiency virus (HIV)-infected men. METHOD: We related both types of optimism to HIV symptoms and to CD4 counts in a cross-sectional study of 78 men, and to change in CD4 counts in a 2-year prospective study of a subsample of these men. RESULTS: Analyses controlled for age, education, employment status, duration since diagnosis, and azidothymidine (AZT) use. The two types of optimism were only minimally related to each other (r=.25). Cross-sectionally, higher levels of both types of optimism were associated with having fewer HIV symptoms, but a more optimistic explanatory style was related to having poorer immune status (lower CD4). Prospectively, an optimistic explanatory style was a substantial predictor of greater decline in CD4 counts after 2 years, after controlling for baseline CD4. Dispositional optimism was unrelated to CD4 counts. Neither health behaviors nor coping strategies mediated these relationships, and the relationships of optimistic explanatory style (and to a lesser extent, dispositional optimism) were independent of negative affectivity. CONCLUSIONS: These optimism measures tap different types of optimism, and although both are related to better subjective health in HIV-infected men, an optimistic explanatory style predicts greater decline in immune status over time. This latter relationship may be related to the unique stress and life experiences associated with having HIV.


Subject(s)
HIV Infections/psychology , Internal-External Control , Motivation , Adult , Aged , CD4 Lymphocyte Count , Disease Progression , HIV Infections/immunology , Humans , Male , Middle Aged , Personality Inventory , Psychoneuroimmunology , Sick Role
8.
Am J Epidemiol ; 146(6): 470-5, 1997 Sep 15.
Article in English | MEDLINE | ID: mdl-9290507

ABSTRACT

Malignancies, particularly Kaposi's sarcoma and non-Hodgkin's lymphoma (NHL), are associated with human immunodeficiency virus (HIV) infection. Cancer incidence among 1,073 asymptomatic HIV-infected individuals from the Pulmonary Complications of HIV Infection Study cohort, persons from six states followed from 1988 to 1994, was examined. Total cancer incidence was 3.99/100 person-years; for Kaposi's sarcoma, incidence was 2.64 cases/100 person-years, and for NHL, it was 1.18 cases/100 person-years. Total cancer (n = 156 cases) was higher among nonblacks than among blacks (rate ratio = 2.8, 95% confidence interval 1.3-6.1), with similar results for Kaposi's sarcoma and NHL. The rate of lung cancer (n = 5) among white, homosexual/bisexual males was 0.18 per 100 person-years, suggesting a high risk of lung cancer.


Subject(s)
HIV Infections/complications , Lymphoma, AIDS-Related/epidemiology , Lymphoma, Non-Hodgkin/epidemiology , Neoplasms/epidemiology , Sarcoma, Kaposi/epidemiology , Adult , Cohort Studies , Female , Humans , Incidence , Lymphoma, AIDS-Related/virology , Lymphoma, Non-Hodgkin/virology , Male , Middle Aged , Neoplasms/virology , Odds Ratio , Sarcoma, Kaposi/virology
10.
Ann Intern Med ; 126(2): 123-32, 1997 Jan 15.
Article in English | MEDLINE | ID: mdl-9005746

ABSTRACT

BACKGROUND: The resurgence of tuberculosis in the United States is largely linked to the human immunodeficiency virus (HIV) epidemic. Despite this link, the epidemiology of tuberculosis and preventive strategies in patients infected with HIV are not completely understood. OBJECTIVES: To determine the incidence and predictors of tuberculosis in HIV-infected persons. DESIGN: Prospective, multicenter cohort study. SETTING: Community-based cohort of persons with and without HIV infection at centers in the eastern, midwestern, and western United States. PARTICIPANTS: 1130 HIV-seropositive patients without AIDS who were followed for a median of 53 months (814 homosexual men, 261 injection drug users, and 55 women who had acquired HIV through heterosexual contact). MEASUREMENTS: Delayed hypersensitivity response to purified protein derivative (PPD) tuberculin and mumps antigen, CD4 T-lymphocyte counts, and frequency of tuberculosis. RESULTS: 31 HIV-seropositive patients developed tuberculosis (0.7 cases per 100 person-years [95% CI, 0.5 to 1.0]). The most important demographic risk factor was location (adjusted risk ratio for eastern compared with midwestern and western United States, 4.1 [CI, 2.0 to 8.4]). Tuberculosis occurred more frequently in persons with CD4 counts of less than 200 cells/mm3 (1.2 cases per 100 person-years [CI, 0.7 to 1.9]) than in those with higher counts (0.5 cases per 100 person-years [CI, 0.3 to 0.8]). The rate of tuberculosis was highest among tuberculin converters (5.4 cases per 100 person-years [CI, 1.1 to 15.7]), lower among patients who were PPD positive at first testing (4.5 cases per 100 person-years [CI, 1.6 to 9.7]), and lowest among patients who remained PPD negative (0.4 cases per 100 person-years [CI, 0.2 to 0.7]). Tuberculosis was not reported among persons who had PPD reactions of 1 to 4 mm. Compared with that of patients who tested positive for mumps, the risk for tuberculosis of those who tested negative was increased about sevenfold if they were PPD positive (P < 0.03) and fourfold if they were PPD negative (P < 0.02). CONCLUSIONS: Incidence of tuberculosis was higher in the eastern United States, in patients with CD4 counts of less than 200 cells/mm3, and in PPD-positive patients. Analysis of tuberculin reaction size supports the current interpretive criteria of the Centers for Disease Control and Prevention. Nonreactivity to mumps antigen indicated increased risk for tuberculosis independent of PPD response.


Subject(s)
AIDS-Related Opportunistic Infections/epidemiology , HIV Seropositivity/epidemiology , Tuberculosis, Pulmonary/epidemiology , AIDS-Related Opportunistic Infections/immunology , Adolescent , Adult , Aged , Antigens, Viral , CD4 Lymphocyte Count , Female , Follow-Up Studies , HIV Seropositivity/immunology , Humans , Incidence , Male , Middle Aged , Mumps/immunology , Prospective Studies , Tuberculin Test , Tuberculosis, Pulmonary/immunology , United States/epidemiology
12.
N Engl J Med ; 335(15): 1099-106, 1996 Oct 10.
Article in English | MEDLINE | ID: mdl-8813040

ABSTRACT

BACKGROUND: We compared two combinations of nucleosides with zidovudine alone in patients with advanced human immunodeficiency virus (HIV) infection. METHODS: A total of 1102 patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter were randomly assigned to receive zidovudine alone or zidovudine combined with either didanosine or zalcitabine. Disease progression, survival, toxic effects, and the CD4 cell response were assessed. RESULTS: After a median follow-up of 35 months, disease progression or death occurred in 62 percent of the 363 patients assigned to zidovudine plus didanosine, 63 percent of the 367 assigned to zidovudine plus zalcitabine, and 66 percent of the 372 assigned to zidovudine only (P=0.24). As compared with zidovudine therapy, treatment with zidovudine plus didanosine was associated with a relative risk of disease progression or death of 0.86 (95 percent confidence interval, 0.71 to 1.03), and treatment with zidovudine plus zalcitabine was associated with a relative risk of 0.92 (95 percent confidence interval, 0.76 to 1.10). Survival was similar in the three groups. In a subgroup analysis, combination therapy delayed disease progression or death in patients who had previously received zidovudine for 12 months or less. Therapy with zidovudine plus didanosine resulted in more gastrointestinal adverse effects, and treatment with zidovudine plus zalcitabine, more neuropathy. The mean increases in CD4 cell counts at two months were higher with combination therapy than with zidovudine alone. CONCLUSIONS: In patients with advanced HIV infection, combination therapy with zidovudine and either didanosine or zalcitabine is not superior to zidovudine therapy alone. However, these combinations may be more effective than zidovudine monotherapy in patients with little or no previous zidovudine treatment.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Antiviral Agents/therapeutic use , Didanosine/therapeutic use , Zalcitabine/therapeutic use , Zidovudine/therapeutic use , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/mortality , Adult , Antiviral Agents/adverse effects , CD4 Lymphocyte Count , Didanosine/adverse effects , Disease Progression , Disease-Free Survival , Drug Therapy, Combination , Female , Humans , Male , Risk , Survival Analysis , Zalcitabine/adverse effects , Zidovudine/adverse effects
13.
AIDS ; 10(11): 1257-64, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8883588

ABSTRACT

OBJECTIVE: To study the overall and cause-specific HIV-related mortality in a cohort of HIV-seropositive subjects according to transmission category, race/ethnicity, sex and severity of immunosuppression. DESIGN: A cohort of 1129 HIV-seropositive homo-/bisexual men, injecting drug users, and female partners of HIV-infected men were enrolled at six centers in San Francisco, Los Angeles, Chicago, Newark, Detroit and New York between 1 November 1988 and 1 November 1989. Subjects were evaluated every 6 months at least until 31 March 1994. METHODS: The analyses of overall mortality for the subgroups of interest were performed with Kaplan-Meier plots and Cox proportional hazards models. Cause-specific analyses were performed on the primary cause of death using rates per 100 person-years of exposure. RESULTS AND CONCLUSIONS: Baseline severity of immunosuppression is the strongest predictor of mortality. There were no statistically significant differences in overall HIV-related mortality among transmission categories, race/ethnicity groups or sexes. There were differences, however, in cause-specific mortality among the different risk groups.


Subject(s)
Bisexuality , HIV Infections/mortality , Homosexuality, Male , Sexual Partners , Substance Abuse, Intravenous , AIDS-Related Opportunistic Infections/complications , CD4 Lymphocyte Count , Cohort Studies , Female , HIV Infections/complications , HIV Infections/transmission , Humans , Male
14.
Article in English | MEDLINE | ID: mdl-8797682

ABSTRACT

We examined the effect of bacterial pneumonia on the magnitude of circulating plasma HIV RNA in HIV-infected patients. Serum samples from 13 adult HIV-infected patients (median CD4 count = 83 cells/microl) were assayed for HIV RNA using the reverse transcriptase polymerase chain reaction assay (a) before bacterial pneumonia, (b) during the acute phase, and (c) after the recovery from the disease. Patients remained on constant antiretroviral therapy: HIV RNA was detected in all samples tested. The medians before, during, and after bacterial pneumonia were 60,000 copies per ml, 245,000 copies per ml, and 84,000 copies per ml, respectively. All 13 patients had increased HIV RNA levels on developing pneumonia. There was a decline in the level of HIV RNA with recovery from pneumonia in 12 of 13 patients. The difference between the HIV RNA levels before and after pneumonia was not significant, nor was there significant difference in the CD4 counts before and after pneumonia. In conclusion, bacterial pneumonia is associated with a consistent, transient increase in HIV RNA of variable magnitude in AIDS patients. Interpretation of HIV RNA changes for clinical management of AIDS patients must take into account this reversible elevation during infections.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/virology , HIV/genetics , Pneumonia, Bacterial/complications , RNA, Viral/analysis , Adult , CD4 Lymphocyte Count , Female , Humans , Male , Middle Aged , Polymerase Chain Reaction , RNA, Viral/blood , Time Factors , Viral Load
15.
J Infect Dis ; 174(2): 401-3, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8699074

ABSTRACT

Human immunodeficiency virus (HIV) load markers are being used increasingly to monitor disease progression and evaluate antiretroviral therapy. This study examined plasma HIV RNA and p24 antigen levels before, during, and after 15 AIDS-associated opportunistic disease events in patients with AIDS (median CD4 cell count = 65/microL). Plasma HIV RNA was detected during 13 of the 15 events (median level before an event = 21,000 copies/mL). There was an increase in the level of plasma HIV RNA with the onset of an AIDS-associated opportunistic disease during 11 of 13 events for which HIV RNA was detectable (median level during an event = 145,000 copies/mL). There was a decline in the level of HIV RNA with the recovery from disease (median level after an event = 29,700 copies/mL). In contrast, there was no consistent or significant change in p24 antigen levels or CD4 cell counts with either the onset of or recovery from an event. Clinical interpretation of plasma HIV RNA changes must take into account this reversible elevation during AIDS-associated opportunistic disease.


Subject(s)
AIDS-Related Opportunistic Infections/virology , Acquired Immunodeficiency Syndrome/virology , HIV Core Protein p24/blood , RNA, Viral/blood , AIDS-Related Opportunistic Infections/complications , Acquired Immunodeficiency Syndrome/complications , Adult , Biomarkers , Female , HIV Core Protein p24/genetics , Humans , Longitudinal Studies , Male , Middle Aged , RNA, Viral/genetics
16.
J Clin Microbiol ; 34(4): 970-2, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8815119

ABSTRACT

We investigated gender as a factor in viral load measurements for human immunodeficiency virus-infected patients. Forty antiretroviral-therapy-naive, age- and CD4-matched women and men were tested for serum RNA and p24 antigen levels prior to antiretroviral therapy and at approximately 12 weeks after therapy. No gender differences were observed for these two markers of viral load.


Subject(s)
HIV Infections/virology , HIV-1/isolation & purification , RNA, Viral/blood , Viremia/virology , Adolescent , Adult , Aged , Antiviral Agents/therapeutic use , Biomarkers , Female , HIV Core Protein p24/blood , HIV Infections/drug therapy , Humans , Male , Middle Aged , Sex Characteristics , Viremia/drug therapy
17.
J Calif Dent Assoc ; 24(3): 53-8, 1996 Mar.
Article in English | MEDLINE | ID: mdl-9063194

ABSTRACT

The classification of mandibular and midface fractures is discussed. Signs and symptoms of fractures are presented and the radiographic examinations described. The latest treatment modalities, including the use of skeletal fixation with titanium plates, are also discussed.


Subject(s)
Jaw Fractures/therapy , Adolescent , Adult , Child , Child, Preschool , Fracture Fixation/methods , Humans , Infant , Jaw Fractures/classification , Male , Mandibular Condyle/injuries , Mandibular Fractures/surgery , Maxillary Fractures/surgery , Maxillofacial Development , Radiography, Dental , Titanium
18.
N Engl J Med ; 333(13): 845-51, 1995 Sep 28.
Article in English | MEDLINE | ID: mdl-7651475

ABSTRACT

BACKGROUND: Patients with human immunodeficiency virus (HIV) infection are at increased risk for bacterial pneumonia in addition to opportunistic infection. However, the risk factors for bacterial pneumonia and its incidence in this population are not well defined. METHODS: In a multicenter, prospective, observational study, we monitored 1130 HIV-positive and 167 HIV-negative participating adults for up to 64 months for pulmonary disease. The HIV-positive group comprised 814 homosexual or bisexual men, 261 injection-drug users, and 55 female partners of HIV-infected men. RESULTS: There were 237 episodes of bacterial pneumonia among the HIV-positive participants (rate, 5.5 per 100 person-years), as compared with 6 episodes among the HIV-negative participants (rate, 0.9 per 100 person-years; P < 0.001). The rate of bacterial pneumonia increased with decreasing CD4 lymphocyte counts (2.3, 6.8, and 10.8 episodes per 100 person-years in the strata with more than 500, 200 to 500, and fewer than 200 cells per cubic millimeter, respectively; P < or = 0.022 for each comparison). Injection-drug users had a higher rate of bacterial pneumonia than did homosexual or bisexual men or female partners. In the stratum with the fewest CD4 lymphocytes, cigarette smoking was associated with an increased rate of pneumonia. Mortality was almost four times higher among participants with an episode of pneumonia than among the others. Prophylaxis with trimethoprim-sulfamethoxazole was associated with a 67 percent reduction in confirmed episodes of bacterial pneumonia (P = 0.007). CONCLUSIONS: Bacterial pneumonia is more frequent in HIV-positive persons than in seronegative controls, and the risk is highest among those with CD4 lymphocyte counts below 200 per cubic millimeter and among injection-drug users.


Subject(s)
AIDS-Related Opportunistic Infections/etiology , HIV Seropositivity/complications , Pneumonia, Bacterial/etiology , AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/prevention & control , CD4 Lymphocyte Count , Case-Control Studies , Female , HIV Seronegativity , HIV Seropositivity/immunology , Humans , Male , Pneumonia, Bacterial/epidemiology , Pneumonia, Bacterial/prevention & control , Prospective Studies , Risk Factors , Smoking/adverse effects , Substance Abuse, Intravenous/complications , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
19.
Clin Infect Dis ; 20(5): 1396-8, 1995 May.
Article in English | MEDLINE | ID: mdl-7620032

ABSTRACT

A 28-year-old male infected with the human immunodeficiency virus (HIV) developed a pleural empyema caused by Cryptococcus neoformans. He responded well to chest-tube drainage and antifungal therapy; he received fluconazole as maintenance therapy for 1 year and has not relapsed. We reviewed the English-language literature on cryptococcal pleural effusions in patients with and without AIDS. Only three other cases of empyema, one of them in an HIV-infected patient, have been reported. A pleural-fluid cryptococcal antigen test was diagnostic in our case and should be included in the diagnostic evaluation of unexplained pleural empyema/effusion in immunocompromised patients.


Subject(s)
AIDS-Related Opportunistic Infections/diagnosis , Cryptococcosis/diagnosis , Empyema, Pleural/diagnosis , Adult , Humans , Male
20.
Am J Respir Crit Care Med ; 151(4): 1068-74, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7697233

ABSTRACT

Pneumocystis carinii pneumonia remains one of the most common opportunistic infections in patients with acquired immune deficiency syndrome (AIDS). Treatment with either intravenous pentamidine or trimethoprim-sulfamethoxazole (TMP-SMX) is frequently complicated by serious adverse reactions. This study was a prospective, blinded comparison of 600 mg/d of pentamidine as an aerosol versus 15 mg/kg/d of trimethoprim plus 75 mg/kg/d of sulfamethoxazole for patients with mild or moderately severe P. carinii pneumonia (alveolar arterial oxygen difference of less than 55 mm Hg). Of 367 participants who were randomized to receive study therapies, 287 had proven and 16 had presumed Pneumocystis pneumonia. There were 29 deaths within 35 d of study initiation: 12 in the aerosolized pentamidine group and 17 in the TMP-SMX groups (log rank p = 0.28). The difference in mortality was 3.4% (95% CI = -3.5, 10.8%). Ninety-four patients treated with aerosolized pentamidine had to have their study therapy changed because of lack of efficacy, compared with 22 patients treated with TMP-SMX (p = 0.002). In addition PaO2 improved faster in patients treated with TMP-SMX. However, aerosolized pentamidine was discontinued less often than TMP-SMX because of toxicity (9.4 versus 40% p < 0.001). Rash (0.6 versus 14.9%), nausea and vomiting (1.7 versus 12.2%), and abnormalities of liver function tests (1.7 versus 12.2%) were the most common adverse effects necessitating treatment discontinuation. During 6-mo. follow-up there was no difference in mortality.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
AIDS-Related Opportunistic Infections/drug therapy , Pentamidine/therapeutic use , Pneumonia, Pneumocystis/drug therapy , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , AIDS-Related Opportunistic Infections/blood , AIDS-Related Opportunistic Infections/mortality , Administration, Inhalation , Double-Blind Method , Female , Humans , Male , Oxygen/blood , Pentamidine/administration & dosage , Pentamidine/adverse effects , Pneumonia, Pneumocystis/blood , Pneumonia, Pneumocystis/mortality , Prospective Studies , Survival Analysis , Treatment Failure , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...